Evidence map›Paper›PMID 42650737›Full record

ArticleAntibiotics (Basel, Switzerland)2026

A Novel Antimicrobial Peptide Displaying Broad-Spectrum Activity Against Pan-Resistant Pathogens and Low Propensity for Resistance Development.

Betul Zehra Temur, Esma Bolat, Meltem Ayas, Sengül Nisa Demirci, Nihan Unubol, Neval Yurttutan Uyar, Ozge Can, Tanil Kocagoz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Betul Zehra TemurDepartment of Biomedical Engineering, Graduate School of Natural and Applied Sciences, Acibadem University, Istanbul 34752, Türkiye.ORCID 0000-0003-4064-2537
Esma BolatDepartment of Medical Biotechnology, Graduate School of Health Sciences, Acibadem University, Istanbul 34752, Türkiye.ORCID 0000-0002-4742-4914
Meltem AyasMedical Laboratory Techniques, Vocational School of Health Services, Acibadem University, Istanbul 34752, Türkiye.
Sengül Nisa DemirciDepartment of Biomedical Engineering, Faculty of Engineering and Natural Sciences, Acibadem University, Istanbul 34752, Türkiye.
Nihan UnubolMedical Laboratory Techniques, Vocational School of Health Services, Acibadem University, Istanbul 34752, Türkiye.ORCID 0000-0003-4644-112X
Neval Yurttutan UyarDepartment of Medical Microbiology, School of Medicine, Acibadem University, Istanbul 34752, Türkiye.
Ozge CanDepartment of Biomedical Engineering, Graduate School of Natural and Applied Sciences, Acibadem University, Istanbul 34752, Türkiye.
Tanil KocagozDepartment of Medical Biotechnology, Graduate School of Health Sciences, Acibadem University, Istanbul 34752, Türkiye.ORCID 0000-0001-7211-2026

Funding

Türkiye Bilimsel ve Teknolojik Araştırma Kurumu 119C036Türkiye Bilimsel ve Teknolojik Araştırma Kurumu 217S060
6 · The paper itself

Abstract

objectivesThe escalation of multidrug-resistant (MDR) clinically relevant bacterial isolates, including

methodsD-TN6 efficacy was evaluated against 164 clinical isolates, including pan-drug-resistant, carbapenem-resistant, and polymyxin-resistant phenotypes. A 20-passage serial induction assay compared resistance development kinetics of D-TN6 against gentamicin over an extended period.

resultsD-TN6 demonstrated potent efficacy against MRSA (minimum inhibitory concentration (MIC)

conclusionsThese findings underscore D-TN6 as a robust therapeutic candidate. Its efficacy against MDR strains and its feature of low propensity for resistance development-likely due to membrane disruption-position D-TN6 as a promising solution for life-threatening infections where conventional last-resort agents fail.

Indexed as

antimicrobial peptideE. coliESKAPE pathogensmulti-drug resistant bacteriapeptide antibioticsprotease resistance

Identifiers

PMID42650737
PMCPMC13510277

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.